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Abstract
A thorough phytochemical study of Stereocaulon evolutum was conducted, for the isolation
of structurally related atranorin derivatives. Indeed, pilot experiments suggested that atra-
norin (1), the main metabolite of this lichen, would interfere with the lifecycle of hepatitis
C virus (HCV). Eight compounds, including one reported for the first time (2), were isolated
and characterized. Two analogs (5, 6) were also synthesized, to enlarge the panel of atra-
norin-related structures. Most of these compounds were active against HCV, with a half-
maximal inhibitory concentration of about 10 to 70 µM, with depsides more potent than
monoaromatic phenols. The most effective inhibitors (1, 5 and 6) were then added at differ-
ent steps of the HCV lifecycle. Interestingly, atranorin (1), bearing an aldehyde function at
C-3, inhibited only viral entry, whereas the synthetic compounds 5 and 6, bearing a hydroxy-
methyl and a methyl function, respectively, at C-3 interfered with viral replication.
Introduction
Hepatitis C virus (HCV) is a small, enveloped virus of genus Hepacivirus, from the Flaviviridae
family. About 170 million people worldwide are chronically infected with HCV, and there are
three to four million new infections each year [1], principally through blood transmission. The
high genetic variability of the virus has hindered vaccine development. However, new treat-
ments have emerged in the last few years, with the discovery of direct-acting antivirals (DAAs),
which were added to the previous standard care procedure based on the use of pegylated inter-
feron (IFN) and ribavirin (RVB). Clinical trials currently underway suggest that IFN-free regi-
mens combining several DAAs will cure almost all cases of hepatitis C, making it possible to
avoid the severe adverse effects of IFN treatment [2]. Nevertheless, the current high cost of
such treatments may restrict them to only the wealthiest patients and nations [3]. There is,
therefore, still a need to develop alternative and complementary approaches to treatment for a
large proportion of patients.
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It has recently been shown that natural compounds may be a source of anti-HCV drugs
[4,5], but the presence of such active molecules has never been investigated in lichens. Lichens
are symbiotic associations between at least one fungal and an algal and/or cyanobacterial part-
ner. Some 1,035 secondary metabolites have been isolated from the 18,500 lichen species from
the Arctic to tropical habitats described to date, and many more compounds remain to be char-
acterized [6]. Most of these compounds are polyketides, polyphenols, quinones or terpenoids,
presumably of fungal origin [6,7], and their biological activities remain largely underexplored.
However, a few have been shown to have antibiotic, antimycobacterial, anti-inflammatory, an-
algesic, antipyretic, or antiproliferative effects [7]. Antiviral activities have also been reported
for some secondary lichen metabolites, such as (+)-usnic acid, sekikaic acid and anthraqui-
nones, targeting Junin and Tacaribe arenaviruses [8], respiratory syncytial virus [9] and herpes
simplex virus type 1 [8], respectively. In a pilot study, we discovered that atranorin seemed to
inhibit HCV. As this depside is a major compound of the genus Stereocaulon, we conducted a
phytochemical investigation on a crude extract of S. evolutum. Seven structurally related atra-
norin derivatives were isolated, together with seven other secondary metabolites. Two atra-
norin analogs were also synthesized. The relationship between structure and antiviral activity
against HCV was discussed with these molecules.
Materials and Methods
General procedures
All solvents for chromatography were purchased from Sigma-Aldrich (France). Thin-layer
chromatography (TLC) was carried out on silica gel plates (Merck silica gel 60F254) with the
B, C, and G standard solvent systems for the identification of substances from lichens [10].
The spots were first visualized under UV light and then after spraying with anisaldehyde–
H2SO4 reagent. Circular chromatography and column chromatography (CC) were carried
out on silica gel (40–63 μm, Kieselgel 60, Merck, 7667). Medium-pressure liquid chromatog-
raphy (MPLC) was conducted on a SPOT Liquid Chromatography Flash apparatus (Armen
Instrument), using prepacked silica gel or RP-18 columns (Chromabond, Merck). 1H, 13C
and 2D NMR spectra were recorded on a BrukerAvance III400 or a Bruker 300 spectrometer
with deuterated solvents. High-resolution mass spectrometry (HR-MS) measurements were
carried out to determine exact mass, on a Bruker Maxis 4G, MicrO-Tof Q 2, a Thermo-fisher
Q-Exactive or a Waters Q-Tof 2 mass spectrometer for chemical ionization. HPLC-ESI and
ESI-MSn mass spectra were obtained with a LCQ Deca ion trap mass spectrometer (Thermo
Finnigan) equipped with an ESI source, in negative ionization mode. The Ion Trap MS sys-
tem was coupled to an HPLC system, including a Surveyor autosampler (Thermo Finnigan),
a 1100 Series binary pump (Agilent Technologies), a UV-6000 DAD UV–visible detector
(Thermo Finnigan) and a Zorbax Eclipse XDB-C18 column (150 mm x 2.1 mm, Agilent
Technologies) maintained at 30°C by a thermostat.
Ethics statement
Specimens of S. evolutum Graewe were collected from siliceous rocks in Saint Just (Ille et
Vilaine, France), by F. Le Dévéhat, in November 2011. No specific permits were required for
the described field studies in Saint Just (Ille et Vilaine). The research sites are not privately
owned or protected in any way and field studies did not involve endangered or protected spe-
cies. A voucher specimen (JB/10/121) has been deposited in the Herbarium of the Department
of Pharmacognosy and Mycology of the University of Rennes 1 (France).
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Extraction and isolation
Air-dried thalli of the lichen S. evolutum Graewe (300 g) were successively extracted with
n-hexane, acetone and tetrahydrofuran, by maceration for one day at room temperature
(3 times x 2 L). A pure white compound 1 (6.2 g) was precipitated from the n-hexane and ace-
tone extracts by evaporating off the solvents at room temperature. The n-hexane filtrate
(1.55 g) was fractionated on successive silica gel columns and circular chromatography, to ob-
tain compounds 15 (7.0 mg), 16 (8.5 mg) and 17 (23.3 mg). The acetone filtrate was concen-
trated down to a volume of 50 mL under vacuum and filtered, to yield a white precipitate P1
(1.5 g) and a soluble portion S1 (4.8 g). The P1 fraction was purified on an MPLCRP-18 col-
umn and subjected to precipitation steps, to yield compounds 11 (25.5 mg) and 13 (1.2 g). The
acetone filtrate S1 (4.8 g) was subjected to repeated MPLC C18 and silica gel MPLC or column
chromatography to isolate compounds 4 (5.2 mg), 7 (159 mg), 8 (6.5 mg), 9 (9.9 mg), 14
(5 mg), 10 (14.5 mg), 12 (7.2 mg), 2 (8.4 mg), and 3 (20,9 mg). Detailed protocols are available
in Supporting Information (S1 Protocol).
Detection of compound 2 by LC-ESI-MS/MS in acetone and ethyl
acetate extracts
Dried ground S. evolutum powder (1 g) was macerated at room temperature in acetone or ethyl
acetate (15 mL) for 24 h. This extraction process was repeated three times. Simultaneously,
pure atranorin (1 g) or a dried ethyl acetate extract (100 mg) was macerated in acetone (15 mL
or 1.5 mL) for one week. Compound 2 was detected in extracts by HPLC-ESI, as previously de-
scribed [11].
Hemisynthesis of atranorin derivatives
Methyl-8-hydroxy-4-O-demethylbarbatate (5): a solution of atranorin (93.5 mg, 0.25 mmol) in
methanol (10 mL, 0.025 M) was stirred at 0°C for a few minutes. Sodium borohydride
(18.9 mg, 0.5 mmol) was then added and the mixture was stirred for a further 1 h at room tem-
perature. The reaction was quenched by adding a few drops of saturated ammonium chloride.
The solvent was evaporated off and the residue was purified on a small column of silica gel and
eluted with a solvent system of petroleum ether-CH2Cl2 (1:9), followed by CH2Cl2 (100%).
Compound 5 (79.3 mg, 84%) was obtained as a white crystalline solid [10,12].
Methyl-4-O-demethylbarbatate (6): a solution of methyl-2,4-dihydroxy-3,6-dimethylbenzo-
ate (compound 7) (147 mg, 0.75 mmol) in anhydrous CH2Cl2 (3.75 mL, 0.2 M) was added
dropwise, at-70°C, to a 1.0 M solution of boron tribromide in anhydrous CH2Cl2 (3 mL,
3 mmol). The reaction mixture was stirred for 12 h at room temperature. It was then hydro-
lyzed with 10 mL of 2 N HCl solution and subjected to extraction with ethyl acetate. The organ-
ic phase was washed with 2 N HCl and then with a saturated NaCl solution, dried over MgSO4,
filtered and evaporated. The residue was passed through a silica gel column, with 20% ethyl ac-
etate-petroleum ether as the eluent. β-orcinol carboxylic acid (103.1 mg, 74%) was obtained as
a white crystalline solid [10]. Trifluoroacetic anhydride (0.5 mL, 8 mmol) was added to a solu-
tion of β-orcinol carboxylic acid (98.3 mg, 0.54 mmol) in anhydrous diethyl ether (5 mL,
0.1 M) under nitrogen, and the mixture was stirred for ten minutes at room temperature. We
then added compound 7 (88.2 mg, 0.45 mmol) and the mixture was stirred for 24 h at room
temperature. The solvent was removed under low pressure and the residue was purified by
chromatography on deactivated silica gel with 30% ethyl acetate/n-hexane, with a gradual in-
crease in polarity to 50% ethyl acetate/n-hexane. Methyl-4-O-demethylbarbatate (6) was ob-
tained as a white solid (24 mg, 15%) [13].
Anti-HCV Lichen Metabolites
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Cell culture
Huh-7.5.1 cells [14] were maintained in Dulbecco's modified Eagle's medium (DMEM) con-
taining 4.5 g/l D-glucose, 4 mM L-glutamine (Life Technologies), supplemented with 100
units/mL penicillin (Life Technologies), 100 μg/mL streptomycin (Life Technologies), non-es-
sential amino acids (Sigma-Aldrich), 1 mMHepes (Life Technologies) and 10% heat-
inactivated fetal calf serum (FCS, Hyclone). Lichen compounds and control HCV inhibitors
(erlotinib from Abcam and telaprevir from Euromedex) were dissolved in dimethyl sulfoxide
(DMSO). In cell viability and HCV in vitro propagation experiments, the final concentration of
DMSO was systematically adjusted to 0.1%. We checked that this amount of DMSO had no ef-
fect on the biological cycle of HCVcc in vitro (data not shown).
Virus production and titration
HCVcc was generated from the FL-J6/JFH-5’C19Rluc2AUbi construct, a monocistronic, full-
length HCV genome that expresses Renilla luciferase [15]. It was produced and titrated as de-
scribed elsewhere [16,17], except for the readout for luciferase activity measurement. Cell via-
bility was evaluated with the Cell Proliferation Reagent WST-1 (Roche), according to the
manufacturer’s instructions. Luciferase assays were performed according to the manufacturer’s
instructions (Promega) and measurements were performed on a Centro XS3 LB960 lumin-
ometer (Berthold Technologies).
Data analysis
Cell viability and viral replication data from at least three independent experiments were ana-
lyzed. The IC50 values of the compounds were determined from dose-response curves generat-
ed with seven to 12 concentrations of each compound. Curves were fitted to the data points by
nonlinear regression analysis and IC50 values were interpolated from the resulting curves with
GraphPad Prism 5.00 software.
Results and Discussion
Phytochemical composition
Phytochemical investigations were carried out on whole thalli of S. evolutum, with the aim of
isolating metabolites structurally similar to atranorin. Briefly, extractions with solvents of in-
creasing polarity (n-hexane, acetone, tetrahydrofuran) yielded three fractions, which were puri-
fied by extensive and repeated column chromatography on silica gel and RP-18, to give 15
compounds (Fig. 1). The structure of the new compound 2 was assigned by detailed spectros-
copy and the structures of the known compounds were determined by comparisons with
published data.
Compound 2 (a white amorphous powder) was found to have a molecular formula of
C22H22O8 on negative HRESIMS (m/z = 413.1237 [M-H]
-), with 11 degrees of unsaturation.
Analysis of the 1H NMR, 13C NMR (Table 1) and HMQC spectra (S1 Fig.) revealed that com-
pound 2 was very similar to atranorin (compound 1), except that it lacked the aldehyde signal
and had additional signals for a ketone group at δC 198.6 (C-10), a methyl group at δH 2.28
(3H, s, H-11) and δC 27.5, and two conjugated aromatic protons at 7.18 (1H, d, J = 16.5 Hz,
H-9) and 7.85 (1H, d, J = 16.5 Hz, H-8), indicating the presence of a trans double bond
(δC 128.7 and 133.1). Extensive analysis of the HMBC spectrum (Fig. 2) indicated that the pro-
tons of the methyl group at δH 2.28 were correlated with C-10 (δC 198.6) and C-9 (δC 128.7).
Moreover, H-9 (δH 7.18) and H-8 (δH 7.85) were correlated with the C-10 carbonyl group.
These data suggest the presence of a methylvinyl ketone chain. Finally, HMBC correlations
Anti-HCV Lichen Metabolites
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from proton H-9 (δH 7.18) to C-3 (δC 107.6), together with correlations from H-8 (δH 7.85) to
C-2 (δC 163.7) and C-4 (δC 162.6) (Table 1) indicated that compound 2 was an atranorin deriv-
ative with a methylvinyl ketone chain substitution at position C-3. Accordingly, compound 2
was formulated as shown (Fig. 2) and was designated (E)-[3-hydroxy-4-(methoxycarbonyl)-
2,5-dimethylphenyl]-2,4-dihydroxy-6-methyl-3-(3-oxobut-1-en-yl) benzoate.
The structural similarity between compound 2 and atranorin suggested that this compound
might be produced during the maceration of S. evolutum in acetone. We tested this hypothesis,
by performing LC-MS analysis on freshly prepared crude acetone and ethyl acetate extracts of S.
evolutum. Compound 2 was found in the crude acetone extract, but was not detected in the ethyl
acetate extract (Fig. 3). Moreover, atranorin and the crude ethyl acetate extract were macerated
for one week in acetone without the detection of even trace amounts of 2, indicating that the for-
mation of compound 2 in acetone required the lichen to be present. Stictic acid and its methylvi-
nyl ketone derivative, isidiophorin, were isolated from the acetone extract. These two compounds
have been consistently reported to be isolated simultaneously in the acetone fraction [22–24].
This suggests that, like compound 2, isidiophorin was probably derived from stictic acid.
Fig 1. Structures of compounds isolated from the lichen S. evolutum and of the semi-synthetic compounds 5–6.
doi:10.1371/journal.pone.0120405.g001
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Two newly reported depsides from the genus Stereocaulon, methyl-3’-methyllecanorate (3)
and cladonioidesin (4) [25], were also identified. Interestingly, these depsides and compound 2
differed from atranorin (1) in terms of their C-3 substitutions. Indeed, the substituent on C-3
consisted of an aldehyde group in 1, a methylvinyl ketone moiety in 2, a proton in 3 and a car-
boxylic group in 4. We therefore synthesized two analogs, one bearing a methyl alcohol group
and the other a methyl group (5 and 6 respectively) on C-3, to evaluate the influence of the de-
gree of oxidation of the C-3 substituent on HCV inhibition. The synthesis of these molecules
was based on the protocol of Pulgarin [26]. Reduction of the CHO group of atranorin generat-
ed compound 5, and esterification of β-orcinol carboxylic acid with compound 7 resulted in
compound 6. Finally, four monoaromatic phenols (methyl- β-orcinol carboxylate (7), methyl
orsellinate (8) [10], atranol (9) and methyl haematommate (10) [10]), were also isolated.
Thus, the phytochemical investigation of Stereocaulon evolutum extracts and the synthesis of
two derivatives yielded a panel of 10 atranorin derivatives for evaluation on hepatitis C virus.
Antiviral activity of atranorin derivatives
We evaluated the anti-HCV activity of the 10 atranorin-related compounds, using a virus
grown in cell culture (HCVcc) with a modification of its genome resulting in expression of the
Renilla luciferase reporter gene [15]. Two control inhibitors, erlotinib and telaprevir, were sys-
tematically included in each experiment. These two compounds are known to interfere with
the entry and replication steps of viral cycle, respectively. The maximum dose of each tested
Table 1. NMR data for compound 2 in DMSO-d6 (400 MHz for 1H and 100 MHz for 13C).
Position δH δC
1 104.2
2 163.7
3 107.6
4 162.6
5 6.50(s) 111.7
6 144.3
7 169.1
8 7.85 (d, 16.5) 133.1
9 7.18 (d, 16.5) 128.7
10 198.6
11 2.28(s) 27.5
12 2.56(s) 23.9
1’ 115.5
2’ 157.2
3’ 116.0
4’ 150.7
5’ 6.76 (s) 115.7
6’ 136.4
7’ 169.5
8’ 1.99 (s) 9.2
9’ 2.34 (s) 20.9
OCH3 3.89 (s) 52.2
2’-OH 10.52 (s)
4-OH 11.50 (brs)
2-OH 12.04 (s)
doi:10.1371/journal.pone.0120405.t001
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compound was 100 μM, because most of these molecules became insoluble in aqueous solution
at higher concentrations. The first experimental procedure used involved the preincubation of
human hepatic Huh-7.5.1 cells for 1 h with various doses of the molecules. The cells were then
cultured in the presence of both the molecules tested and the virus, for an additional 48 h. At
the end of the incubation period, we assessed cell viability and viral replication. This protocol
made it possible to test the effects of molecules on both virus entry and replication. Initial ob-
servations indicated that most compounds were not cytotoxic (Table 2 and S2 Fig.). For com-
pounds 1, 4, 8, 9 and 10, high doses led to a minimal loss of signal, due to either weak toxicity
or an antiproliferative effect similar to that observed for erlotinib, an epidermal growth factor
receptor inhibitor. Conversely, compounds 3 and 5 were more toxic, with estimated half-
maximal cytotoxicity concentrations (CC50) of 82 μM and 106 μM, respectively (Table 2). Re-
markably, compound 6 tended to give a slightly, but reproducibly higher viability signal when
used at high doses, with a peak at about 50 μM. This probably reflects a modest stimulation of
cell proliferation, an effect due solely to the lichen metabolite, because a similar profile was ob-
served in the absence of viral infection (data not shown). At concentrations greater than
50 μM, cytotoxic effects emerged, as shown by the decrease of the viability signal.
With the exception of cladonioidesin (4), all the atranorin derivatives inhibited HCV in a
dose-dependent manner. Thus, the half-maximal inhibitory concentrations (IC50) of lichen de-
rivatives ranged between about 10 and 70 μM, whereas those of the controls were consistent
with published values [27–29] (Table 2). The IC50 values of these lichen metabolites were simi-
lar to those published for other natural molecules [4]. The high standard error of the mean
(SEM) observed for the IC50 of compound 2 probably resulted from the observed instability of
the molecule in solution, even if dissolved immediately before use. Monoaromatic phenols and
depsides had different IC50 values (Table 2). With the exception of compound 2, which was in-
stable, depsides appeared to be more active than monoaromatic phenols, and this finding was
confirmed statistically by an analysis of variance (Table 2, S1 Table). The lipophilicity of these
lichen metabolites may govern their efficacy in the targeted cells, by influencing their passive
diffusion across the cell membrane, and thus their intracellular bioavailability. We used
ALOGPS 2.1 freeware to predict the theoretical partition coefficient (logP) of the studied
Fig 2. HMBC key correlations for compound 2.
doi:10.1371/journal.pone.0120405.g002
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Fig 3. LC-MS analysis. Compound 2 (extracted at Rt = 19.48 min) was detected through PDA chromatograms (total scan at λ = 220–600 nm), base-peak
mass chromatograms and MS spectra of extemporaneously prepared acetone extract of S. evolutum (a), an ethyl acetate extract of S. evolutum (b) and pure
atranorin macerated in acetone for one week (c).
doi:10.1371/journal.pone.0120405.g003
Anti-HCV Lichen Metabolites
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atranorin derivatives, to obtain an index of lipophilicity. Depsides, which had higher levels of
antiviral activity, were also more lipophilic than monoaromatic phenols (S3 Fig.). By contrast,
lipophilicity was not a discriminant parameter within the depside family tested. However, our
results highlight the importance of the nature of the chemical group at position C-3 in depsides
for their anti-HCV activity, as these molecules have identical chemical structures except for
this position. The most active depsides (1, R = CHO, IC50 = 22.3 μM; 5, R = CH2OH, IC50 =
11.8 μM and 6, R = CH3, IC50 = 13.3 μM) were selected for additional investigations. We ex-
cluded molecule 3 from further analysis because its selectivity index (SI, ratio of CC50 to IC50)
was below that of compound 5 (Table 2).
Targeted stages of the HCV life cycle
An experimental procedure was designed to determine the inhibitor class (entry or replication)
to which compounds 1, 5 and 6 belonged. HCVcc were added to the cell culture during a limit-
ed time window (around 17 h). The cells were then washed to eliminate viruses from the inocu-
lum and viral replication was allowed to take place for an additional 30 h. The selected
compounds were present in the culture medium during inoculation (I), replication (R), or both
these phases (inoculation and replication, I/R). The reference drugs and compound 1 had no ef-
fect on cell viability, regardless of the incubation conditions (Fig. 4A). A small anti-proliferative
effect was detectable only with high doses of erlotinib. The cytotoxic effect of compound 5 was
also reproduced in these new conditions, with a similar CC50 (~ 100 μM). Periods of more than
17 h (R and I/R) of incubation with compound 6 resulted in an enhancement of the cell viability
signal over a narrow range of high concentrations, probably reflecting the capacity of this mole-
cule to induce cell proliferation, as reported above. At a concentration of 100 μM, this com-
pound induced some cytotoxicity, as demonstrated by a decrease in signal intensity, except in R
conditions, in which the toxic effect was shifted to higher concentrations. In terms of antiviral
activity, we expected to obtain two inhibition profiles for the luminescence signal, depending
Table 2. Anti-HCV activity and toxicity of atranorin derivativesa.
Viability at
Compounds IC50 (μM) 50 μM 100 μM CC50 (μM) SI
Depsides 1 22.3 ±8.0 95.9 ±4.5 91.8 ±5.9 >100 -
2 64.5 ±26.5 110.2 ±5.9 107.4 ±5.7 >100 -
3 25.4 ±1.7 52.7 ±0.6 63.1 ±2.9 81.9 ±13.6 3.2
4 NI 104.0 ±2.5 90.4 ±3.4 >100 -
5 11.8 ±1.1 88.4 ±7.3 55.8 ±5.9 105.8 ±7.3 8.9
6 13.3 ±1.6 144.7 ±3.2 81.6 ±20.6 >100 -
Monoaromatic 7 50.6 ±5.0 101.2 ±5.6 97.3 ±6.2 >100 -
phenols 8  100 105.5 ±2.9 93.4 ±4.2 >100 -
9 40.3 ±0.6 91.1 ±3.5 78.7 ±2.3 >100 -
10 55.5 ±7.9 88.1 ±5.5 72.2 ±2.0 >100 -
5 μM 10 μM
Controls Telaprevir 0.18 ±0.02 101.9 ±0.9 94.1 ±4.0 - -
Erlotinib 0.64 ±0.18 96.5 ±4.7 86.5 ±5.1 - -
aCompounds were included in antiviral activity and viability assays based on the infection of Huh-7.5.1 cells with HCVcc. The results presented are the
means ± SEM from three sets of experiments. NI, no inhibition. For compounds found to be cytotoxic at the doses tested, we determined the CC50 and SI
(selectivity index).
doi:10.1371/journal.pone.0120405.t002
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Fig 4. Effects of compounds 1, 5 and 6 on cell viability and HCV propagation in vitro.One day after
seeding at 50,000 cells/cm2, Huh-7.5.1 cells were infected with HCVcc at a MOI ~ 0.03 for 17 h (inoculation
phase: I). The inoculum was removed and cell cultures were washed before the addition of newmedium and
incubation for an additional 30 h (replication phase: R). Compounds were present at various concentrations
either during both phases (I/R: black circles and solid lines) or during only one phase (I: black squares and
Anti-HCV Lichen Metabolites
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on the step of the viral lifecycle targeted by the drug (Fig. 4B). As shown with erlotinib, inhibi-
tors of viral entry are most efficient if present at least during the initial interaction between cells
and viruses (conditions I/R and I). The inhibitory effect on the establishment of replication
(R conditions) observed at high doses was probably due principally to the inhibition of new in-
fection cycles initiated by virions produced by cells infected with the inoculum. A different pro-
file was obtained for telaprevir. This antiviral drug specifically targets the HCV protease,
accounting for its inhibitory action regardless of the experimental conditions (I or R). Its pres-
ence in the medium from inoculation onwards prevented the priming of the infection process
at the viral polyprotein maturation step, which normally takes place after the translation of the
HCV genome issued from the infecting virus. This maturation step is also repeated during the
replication phase, for amplification of the viral genome and virion assembly. It is therefore not
surprising that inhibition was strongest when telaprevir was present throughout the viral life-
cycle (I/R), as there was probably an additive effect. Surprisingly, differences were observed be-
tween the lichen metabolites tested. Compounds 5 and 6 had profiles typical of replication
inhibitors, whereas compound 1 had effects similar to those of erlotinib (Fig. 4B). However, no
inhibitory effect was observed when compound 1 was present in the culture medium only dur-
ing inoculation. Had compound 1 been soluble enough to allow the evaluation of higher con-
centrations, its presence during the inoculation stage would probably have led to inhibition, as
for erlotinib. These data again highlight the importance of the nature of the chemical moiety at
C-3 in depsides for their anti-HCV activity. The chemical group in this position seems to influ-
ence not only the potency of the molecule, but also its mechanism of action. Further studies are
required to identify the processes involved because, for example, we cannot rule out a role in
the inhibition of viral entry for compounds 5 and 6, even though they appeared to act as repli-
cation inhibitors in this experiment. It could be hypothesized that the replacement of a methyl
or hydroxymethyl by an aldehyde group in position C-3 would lead to a loss of replication inhi-
bition, but maintenance of the ability to inhibit viral entry.
We show here, for the first time that compounds from lichens, such as atranorin, may dis-
play antiviral activity against HCV. Atranorin has already been described as an antioxidant
[30], antinociceptive [31], antimalarial [32] and anti-inflammatory [33,34] compound. Our
findings reveal that this molecule and some of its derivatives are potential new lead compounds
for the development of anti-HCV drugs. Further studies of the antiviral properties of these
molecules are required, but it is already known that atranorin is a common secondary metabo-
lite of lichens, available in great amounts and easy to purify from lichens with a worldwide dis-
tribution. The next step will be determining the mechanisms of action of these molecules,
which may act directly on viral particles (virucidal effect) or indirectly through effects on viral
or cellular factors involved in HCV propagation. Evaluations of the spectrum of activity of
these molecules against the various viral genotypes will also be required. It will also be impor-
tant to determine the capacity of these molecules to limit the emergence of mutant resistant vi-
ruses to assess their therapeutic potential. Such studies may also provide information about
both the mechanism of action of these molecules and the viral factor targeted. Multitherapy ap-
proaches are required to treat hepatitis C [2], so studies exploring the combination of these
molecules with the various existing drugs will be required, to determine whether particular
combinations have additive, synergistic or antagonistic effects. Despite the tremendous
dotted lines; R: black triangles and dashed lines). (A) Cell viability and (B) viral replication were assessed at
the end of the incubation period. Results are expressed as percentages (mean ± SEM; n = 3) of the mean
values obtained for the respective control cultures, in which cells were incubated with vehicle (0.1% DMSO)
alone. Erlotinib and telaprevir were used as positive antiviral drug controls inhibiting the entry and replication
steps, respectively.
doi:10.1371/journal.pone.0120405.g004
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progress in treatment achieved in recent years with the advent of DAAs, studies are continuing
and new antiviral drugs are still being discovered [35–39]. For instance, new candidate drugs
with different mechanisms of action are currently being investigated [40]. These drugs will
make it possible to diversify the treatments on offer, to cut costs, to improve resistance control
and to resolve the remaining difficult-to-treat cases, particularly those in non-responders with
advanced fibrosis and re-infected transplant patients. This research falls within the scope of ef-
forts to find affordable natural anti-HCV compounds for the treatment of hepatitis C in devel-
oping countries, where this disease remains a major public health problem.
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